0001179110-13-005087.txt : 20130313
0001179110-13-005087.hdr.sgml : 20130313
20130313193755
ACCESSION NUMBER: 0001179110-13-005087
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20130311
FILED AS OF DATE: 20130313
DATE AS OF CHANGE: 20130313
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: WOOD JULIANNA R
CENTRAL INDEX KEY: 0001282660
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-28298
FILM NUMBER: 13688762
MAIL ADDRESS:
STREET 1: 3031 RESEARCH DR
STREET 2: BLDG A
CITY: RICHMOND
STATE: CA
ZIP: 84806
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ONYX PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0001012140
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 943154463
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 249 E. GRAND AVE.
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: 650-266-0000
MAIL ADDRESS:
STREET 1: 249 E. GRAND AVE.
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
4
1
edgar.xml
FORM 4 -
X0306
4
2013-03-11
0
0001012140
ONYX PHARMACEUTICALS INC
ONXX
0001282660
WOOD JULIANNA R
C/O ONYX PHARMACEUTICALS, INC.
249 E. GRAND AVE.
SOUTH SAN FRANCISCO
CA
94080
0
1
0
0
VP, Public Affairs
Common Stock
2013-03-11
4
M
0
820
28.55
A
19039
D
Common Stock
2013-03-11
4
M
0
766
30.28
A
19805
D
Common Stock
2013-03-11
4
M
0
547
35.18
A
20352
D
Common Stock
2013-03-11
4
M
0
1198
37.68
A
21550
D
Common Stock
2013-03-11
4
S
0
3331
85.65
D
18219
D
Common Stock
200
I
Children's Trust
Stock Option (Right to Buy)
28.55
2013-03-11
4
M
0
820
0.00
D
2019-03-31
Common Stock
820
2393
D
Stock Option (Right to Buy)
30.28
2013-03-11
4
M
0
766
0.00
D
2020-03-31
Common Stock
766
7910
D
Stock Option (Right to Buy)
35.18
2013-03-11
4
M
0
547
0.00
D
2021-03-31
Common Stock
547
13307
D
Stock Option (Right to Buy)
37.68
2013-03-11
4
M
0
1198
0.00
D
2022-03-29
Common Stock
1198
20364
D
Shares sold pursuant to a 10b5-1 plan.
12.5% of the shares subject to the option become exercisable 6 months following the date of grant. The remaining shares become exercisable in equal monthly installments over the following 42 months for a total vesting schedule of 48 months.
/s/ Warren DeSouza, Attorney-in-fact
2013-03-12